Nanjing Vazyme Biotech Co., Ltd. (688105.SS)
CNY 23.21
(-1.9%)
CNY 23.21
(-1.9%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.69 Billion CNY | 21.71% |
| 2022 | 1.39 Billion CNY | 190.33% |
| 2021 | 479.82 Million CNY | 71.81% |
| 2020 | 279.27 Million CNY | 124.65% |
| 2019 | 124.31 Million CNY | 46.82% |
| 2018 | 84.66 Million CNY | 125.34% |
| 2017 | 37.57 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 959.42 Million CNY | 0.51% |
| 2024 Q1 | 1.41 Billion CNY | -16.5% |
| 2024 Q2 | 954.58 Million CNY | -32.57% |
| 2023 Q2 | 1.73 Billion CNY | -1.63% |
| 2023 FY | 1.69 Billion CNY | 21.71% |
| 2023 Q4 | 1.69 Billion CNY | 0.06% |
| 2023 Q3 | 1.69 Billion CNY | -2.56% |
| 2023 Q1 | 1.76 Billion CNY | 26.89% |
| 2022 Q2 | 844.05 Million CNY | -6.05% |
| 2022 Q1 | 898.45 Million CNY | 87.24% |
| 2022 FY | 1.39 Billion CNY | 190.33% |
| 2022 Q4 | 1.39 Billion CNY | 24.52% |
| 2022 Q3 | 1.11 Billion CNY | 32.55% |
| 2021 FY | 479.82 Million CNY | 71.81% |
| 2021 Q2 | 407.23 Million CNY | 3.56% |
| 2021 Q4 | 479.82 Million CNY | 19.51% |
| 2021 Q3 | 401.48 Million CNY | -1.41% |
| 2021 Q1 | 393.24 Million CNY | 40.81% |
| 2020 FY | 279.27 Million CNY | 124.65% |
| 2020 Q4 | 279.27 Million CNY | 0.0% |
| 2020 Q2 | 295.93 Million CNY | 0.0% |
| 2019 FY | 124.31 Million CNY | 46.82% |
| 2018 FY | 84.66 Million CNY | 125.34% |
| 2017 FY | 37.57 Million CNY | 0.0% |